INHIBITING 11(BETA)-HSD1 WITH CITRUS FLAVONOIDS

Abstract

A therapeutically effective dose of polymethoxylated flavones, for example in the form of citrus peel extract, is provided for reducing the activity of 11(beta)-HSD1. Reducing the activity of 11(beta)-HSD1 in turn undesirable excess glucocorticoid, e.g. cortisol, levels. Particularly, the PMFs can be effectively used to inhibit a rise in glucocorticoids associated with the stress of weight loss. The polymethoxylated flavones may include one or more of tangeretin, nobiletin, and sinensetin. The PMFs may be administered in any of a variety of known modes of administrations such as oral and topical.

Description

Claims

1. A method for preventing or treating conditions enhanced by the presence of excess glucocorticoids, comprising: administering to a mammal in need thereof a therapeutically effective dose of citrus peel extract for reducing the activity of the enzyme 11(beta)-HSD1, the citrus peel extract comprising at least about 10 mg of polymethoxylated flavones (PMFs).

2. The method of claim 1, further comprising: administering to a mammal the effective dose of citrus peel extract for reducing the activity of 11(beta)-HSD1 at least once a day for a period of at least two weeks.

3. The method of claim 1, wherein the therapeutically effective dose of citrus peel extract comprises from about 100 mg to about 500 mg.

4. The method of claim 1, wherein the citrus peel extract comprises: from about 5 mg to about 20 mg tangeretin;from about 5 mg to about 20 mg nobiletin; andfrom about 2 mg to about 10 mg sinensetin.

5. The method of claim 1, wherein administering to a mammal an effective dose of citrus peel extract further comprises placing the citrus peel extract in an oral dosage form for administration, the oral dosage form comprising a liquid shake or a powdered mix having one or more additional ingredients suitable for forming a shake when mixed with a liquid.

6. The method of claim 1, wherein administering to a mammal an effective dose of citrus peel extract further comprises placing the citrus peel extract in an oral dosage form for administration, the oral dosage form selected from the group consisting of a beverage, a tablet, a capsule, a powder, a confectionary, and a supplemented food.

7. The method of claim 1, wherein administering to a mammal an effective dose of citrus peel extract further comprises placing the citrus peel extract in a topical dosage form for topical administration.

8. A composition of matter, comprising: an effective dose of polymethoxylated flavones (PMFs) for reducing the activity of 11(beta)-HSD1.

9. The composition of matter of claim 8, wherein the PMFs comprise at least about 10 mg PMFs.

10. The composition of matter of claim 8, wherein the PMFs comprise at least about 80 mg polymethoxylated flavones (PMFs).

11. The composition of matter of claim 8, wherein the PMFs comprise at least one of tangeretin, nobiletin, and sinensetin.

12. The composition of matter of claim 11, wherein the PMFs comprise: from about 5 mg to about 20 mg tangeretin;from about 5 mg to about 20 mg nobiletin; andfrom about 2 mg to about 10 mg sinensetin.

13. The composition of matter of claim 8, further comprising one or more additives selected from the group consisting of: ginseng, caffeine, guarana, green tea extract, chromium, vanadium, and CLA.

14. A packaged supplement for treating conditions associated with glucocorticoid excess, comprising: (a) a container which holds a plurality of the effective doses of PMFs for reducing the activity of 11(beta)-HSD1 as defined as in claim 8; and (b) instructions for using the doses.

15. The packaged supplement of claim 14, wherein each of the plurality of doses is separately packaged.

16. The packaged supplement of claim 14, wherein the plurality of doses comprise a single volume of liquid and the instructions for using the dietary supplement comprises instructions for metering and consuming a proper dose.

17. The packaged supplement of claim 14, wherein the dietary supplement comprises a topical treatment for administering the citrus peel extract transdermally.

18. A method for promoting weight loss in a mammal, the method comprising: administering to a mammal participating in a weight loss exercise routine a diet consisting of a caloric intake that is insufficient to maintain the mammal's weight; andadministering to the mammal a composition of matter as defined as in claim 8.

19. A dietary supplement, comprising: a dietary acceptable carrier prepared in a dosage form selected from the group consisting of a liquid, a tablet, a capsule, a powder, a confectionary, and a supplemented food; andat least about 10 mg of polymethoxylated flavones.

20. A method for treating or ameliorating adverse symptoms in mammals associated with excess glucocorticoids, the method comprising administering daily for a plurality of days a dietary supplement as defined as in claim 19.